JP2011522029A - カンナビノイドの組合せの抗腫瘍効果 - Google Patents
カンナビノイドの組合せの抗腫瘍効果 Download PDFInfo
- Publication number
- JP2011522029A JP2011522029A JP2011512222A JP2011512222A JP2011522029A JP 2011522029 A JP2011522029 A JP 2011522029A JP 2011512222 A JP2011512222 A JP 2011512222A JP 2011512222 A JP2011512222 A JP 2011512222A JP 2011522029 A JP2011522029 A JP 2011522029A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- thc
- cbd
- use according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
【選択図】図1
Description
大麻植物抽出物形態のテトラヒドロカンナビノール(THC)及びカンナビジオール(CBD)を100mMの濃度までエタノール中に溶解し、これを必要になるまで−20℃で保存した。
表1:培養液中のヒトU87MG星状細胞腫細胞の細胞生存率
本実験は、THC抽出物とCBD抽出物との組合せが、細胞成長の阻害に対して抽出物単独と同程度の効果があるか否かを試験した。
図1は、THC抽出物単独及びCBD抽出物単独、並びに互いの組合せに対するヒトU87MG星状細胞腫細胞の細胞生存率を示す棒グラフを詳述している。
本実験は、THC抽出物とCBD抽出物との組合せがin vivoでも効果的であるか否かを試験した。
表2:処理15日後のゼロ時間と比べた腫瘍体積
THC、CBD及びTHCとCBDとの1:1比の混合の作用を、2つの細胞株:U87MG及びT98Gにおいて種々の濃度で試験した。細胞生存率のデータを図2a及び図2bに示す。
THCは、ATG1遺伝子及び汎カスパーゼ(pan-caspase)が関与するシグナル伝達経路を使用して細胞死を誘導することが知られている。S6リン酸化、LC3脂質化及びATG1及び汎カスパーゼ阻害剤の効果を調べる研究結果をそれぞれ図3a、図3b及び図3cに示す。
・mTORC1活性を阻害し(S6リン酸化レベルによって決定される)、
脂質化形態のLC3の集積(自食作用(autophagy)の特徴)を促進する、
ことが分かる。
Claims (12)
- がんの治療における使用のための薬剤の製造におけるカンナビノイドの組合せの使用。
- 前記カンナビノイドの組合せが、テトラヒドロカンナビノール(THC)及びカンナビジオール(CBD)を含む、請求項1に記載の使用。
- 前記THC及び前記CBDの比が20:1〜1:20(THC:CBD)である、請求項2に記載の使用。
- 前記THC及び前記CBDの比がおよそ1:1である、請求項2に記載の使用。
- カンナビノイド含有量が、存在する総カンナビノイドが5mg〜100mgの範囲である、請求項1〜4のいずれか一項に記載の使用。
- 各カンナビノイドを単独で使用する場合最適以下(sub-optimal)であると考えられるレベルで使用する、請求項1〜5のいずれか一項に記載の使用。
- 治療対象の前記がんが脳腫瘍である、請求項1〜6のいずれか一項に記載の使用。
- 前記脳腫瘍が神経膠腫である、請求項7に記載の使用。
- 前記脳腫瘍が多形性膠芽腫(GBM)である、請求項8に記載の使用。
- 前記1つ又は複数のカンナビノイドが植物抽出物として、純粋な化合物として、又はそれらの2つの組合せとして存在する、請求項1に記載の使用。
- 前記植物抽出物が植物性薬品物質の形態である、請求項10に記載の使用。
- 前記1つ又は複数のカンナビノイドを互いに別個に、順次又は同時に投与する、請求項1〜11のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0810195.8A GB2471987B (en) | 2008-06-04 | 2008-06-04 | Anti-tumoural effects of cannabinoid combinations |
GB0810195.8 | 2008-06-04 | ||
PCT/GB2009/050621 WO2009147439A1 (en) | 2008-06-04 | 2009-06-04 | Anti-tumoural effects of cannabinoid combinations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011522029A true JP2011522029A (ja) | 2011-07-28 |
JP5611196B2 JP5611196B2 (ja) | 2014-10-22 |
Family
ID=39638149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011512222A Active JP5611196B2 (ja) | 2008-06-04 | 2009-06-04 | カンナビノイドの組合せの抗腫瘍効果 |
Country Status (21)
Country | Link |
---|---|
US (4) | US8632825B2 (ja) |
EP (2) | EP2318000A1 (ja) |
JP (1) | JP5611196B2 (ja) |
KR (2) | KR20160103148A (ja) |
CN (1) | CN102083430B (ja) |
AR (1) | AR072003A1 (ja) |
AU (1) | AU2009254936B2 (ja) |
BR (1) | BRPI0913384A2 (ja) |
CA (1) | CA2726258C (ja) |
CO (1) | CO6382172A2 (ja) |
GB (1) | GB2471987B (ja) |
IL (1) | IL209738B (ja) |
MX (1) | MX2010012557A (ja) |
MY (1) | MY156444A (ja) |
NZ (1) | NZ589228A (ja) |
RU (1) | RU2546284C2 (ja) |
SG (2) | SG195650A1 (ja) |
TW (1) | TWI445531B (ja) |
UA (1) | UA104426C2 (ja) |
WO (1) | WO2009147439A1 (ja) |
ZA (1) | ZA201008556B (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144475A1 (en) | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
GB2475183B (en) * | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
GB201117956D0 (en) | 2011-10-18 | 2011-11-30 | Otsuka Pharma Co Ltd | Phytocannabinoids for use in the treatment of breast cancer |
EP2719375A1 (en) * | 2012-10-10 | 2014-04-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms |
WO2014100231A1 (en) | 2012-12-18 | 2014-06-26 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
GB2516814B (en) * | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
WO2015065544A1 (en) | 2013-10-29 | 2015-05-07 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
JP6659933B2 (ja) | 2014-05-29 | 2020-03-04 | フレッシュ・カット・ディベロップメント・エル・エル・シー | 安定なカンナビノイド製剤 |
GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
WO2016054268A1 (en) | 2014-09-30 | 2016-04-07 | MJAR Holdings, LLC | Methods of growing cannabaceae plants using artificial lighting |
US10406186B2 (en) | 2015-01-31 | 2019-09-10 | Constance Therapeutics, Inc. | Cannabis oil extracts and compositions |
US10238745B2 (en) | 2015-01-31 | 2019-03-26 | Constance Therapeutics, Inc. | Cannabinoid composition and products including α-tocopherol |
EP3067058A1 (en) | 2015-03-13 | 2016-09-14 | Farmagens Health Care Srl | Biological composition based on engineered lactobacillus paracasei subsp. paracasei f19 for the biosynthesis of cannabinoids |
US10934554B2 (en) | 2015-05-28 | 2021-03-02 | Tweed, Inc. | Cannabis plants having modified expression of THCA synthase |
US10123973B2 (en) * | 2015-06-11 | 2018-11-13 | Mashhad University Of Medical Science | Liposome composition for cancer treatment |
CA2988869A1 (en) * | 2015-06-11 | 2016-12-15 | One World Cannabis Ltd | Novel cannabinoid combination therapies for multiple myeloma (mm) |
AU2016295728B2 (en) * | 2015-07-22 | 2020-07-23 | Phytopharma International Ltd. | Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby |
EP3153160B1 (en) | 2015-10-08 | 2021-08-11 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
AU2016347662B2 (en) * | 2015-10-27 | 2021-12-02 | Akos Biosciences, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
AU2016359160A1 (en) * | 2015-11-24 | 2018-06-14 | Constance Therapeutics, Inc. | Cannabis oil compositions and methods for preparation thereof |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
CA3056286A1 (en) * | 2017-03-16 | 2018-09-20 | CannTab Therapeutics Limited | Modified release multi-layer tablet cannabinoid formulations |
US10688191B2 (en) | 2018-01-19 | 2020-06-23 | Hr Biomed, Llc | Delivery of a chemotherapy agent across the blood-brain barrier |
WO2019152736A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
WO2019227167A1 (en) * | 2018-06-01 | 2019-12-05 | The University Of Sydney | Compositions and treatments |
EP3864000A4 (en) | 2018-10-10 | 2022-08-10 | Treehouse Biosciences, Inc. | CANNABIGEROL SYNTHESIS |
WO2020129043A1 (en) * | 2018-12-19 | 2020-06-25 | Pathway RX Inc. | Novel cannabis sativa lines and extracts with anti-cancer properties |
IL272078A (en) * | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
CN111773390B (zh) * | 2020-07-01 | 2021-08-20 | 南京大学 | 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用 |
EP4326253A1 (en) * | 2021-04-19 | 2024-02-28 | The Regents of The University of California | Cannabis limits cancer stem cell growth in poorly differentiated cancers |
WO2023062634A1 (en) * | 2021-10-13 | 2023-04-20 | G.R.I.N Ultra Ltd | Compositions comprising cannabinoids and methods of use thereof in the treatment of cancer |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529892A (ja) * | 2001-03-06 | 2004-09-30 | フォルシュングスインスティトゥート、ヒスチア、フェライン、フユール、クレプスフォルシュング | アサ抽出物から製造される医薬組成物 |
WO2006037981A1 (en) * | 2004-10-01 | 2006-04-13 | Gw Pharma Limited | Inhibition of tumour cell migration |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566560B2 (en) * | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
ES1045342Y (es) | 2000-02-11 | 2001-02-16 | Alvarez Manuel Couto | Expositor giratorio para postales, fotos y similares. |
US20040039048A1 (en) * | 2000-02-11 | 2004-02-26 | Manuel Guzman Pastor | Therapy with cannabinoid compounds for the treatment of brain tumors |
ES2164584A1 (es) * | 2000-02-11 | 2002-02-16 | Univ Madrid Complutense | Terapia con cannabinoides para el tratamiento de tumores cerebrales. |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
US7429457B2 (en) * | 2000-09-14 | 2008-09-30 | The Regents Of The University Of California | Id-1 and Id-2 genes and products as markers of epithelial cancer |
GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
US7025992B2 (en) * | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
US20080057117A1 (en) | 2002-02-15 | 2008-03-06 | Forschungs Institut Miscia Verenfur Krebsforschung | Pharmaceutical composition made up of cannibus extracts |
IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
WO2003091189A1 (en) * | 2002-04-25 | 2003-11-06 | Virginia Commonwealth University | Cannabinoids |
US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
GB2394894B (en) | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
GB2414933B (en) | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
AU2006231452B2 (en) | 2005-04-01 | 2011-05-26 | Intezyne Technologies, Inc. | Polymeric micelles for drug delivery |
US7968594B2 (en) * | 2005-04-27 | 2011-06-28 | Gw Pharma Limited | Pharmaceutical compositions for the treatment of pain |
WO2006124698A2 (en) * | 2005-05-13 | 2006-11-23 | Unimed Pharmaceuticals, Inc. | Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting |
GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
WO2008144475A1 (en) * | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2475183B (en) * | 2008-06-04 | 2011-11-23 | Gw Pharma Ltd | Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators |
-
2008
- 2008-06-04 GB GB0810195.8A patent/GB2471987B/en active Active
-
2009
- 2009-06-03 TW TW098118351A patent/TWI445531B/zh active
- 2009-06-03 AR ARP090102000A patent/AR072003A1/es unknown
- 2009-06-04 BR BRPI0913384-4A patent/BRPI0913384A2/pt not_active Application Discontinuation
- 2009-06-04 RU RU2010153576/15A patent/RU2546284C2/ru not_active IP Right Cessation
- 2009-06-04 UA UAA201015971A patent/UA104426C2/uk unknown
- 2009-06-04 JP JP2011512222A patent/JP5611196B2/ja active Active
- 2009-06-04 KR KR1020167022577A patent/KR20160103148A/ko not_active Application Discontinuation
- 2009-06-04 EP EP09757811A patent/EP2318000A1/en not_active Withdrawn
- 2009-06-04 MX MX2010012557A patent/MX2010012557A/es active IP Right Grant
- 2009-06-04 WO PCT/GB2009/050621 patent/WO2009147439A1/en active Application Filing
- 2009-06-04 US US12/996,124 patent/US8632825B2/en active Active
- 2009-06-04 AU AU2009254936A patent/AU2009254936B2/en active Active
- 2009-06-04 NZ NZ589228A patent/NZ589228A/xx unknown
- 2009-06-04 CA CA2726258A patent/CA2726258C/en active Active
- 2009-06-04 EP EP20201377.7A patent/EP3785710A1/en active Pending
- 2009-06-04 KR KR1020117000057A patent/KR101801639B1/ko active IP Right Grant
- 2009-06-04 MY MYPI2010005534A patent/MY156444A/en unknown
- 2009-06-04 CN CN200980120759.0A patent/CN102083430B/zh active Active
- 2009-06-04 SG SG2013082474A patent/SG195650A1/en unknown
- 2009-06-04 SG SG2013043096A patent/SG191644A1/en unknown
-
2010
- 2010-11-29 ZA ZA2010/08556A patent/ZA201008556B/en unknown
- 2010-12-02 IL IL209738A patent/IL209738B/en active IP Right Grant
- 2010-12-15 CO CO10157623A patent/CO6382172A2/es not_active Application Discontinuation
-
2013
- 2013-11-14 US US14/079,994 patent/US20140287067A1/en not_active Abandoned
-
2015
- 2015-01-14 US US14/596,725 patent/US20150313867A1/en not_active Abandoned
-
2019
- 2019-06-07 US US16/434,616 patent/US20200138771A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529892A (ja) * | 2001-03-06 | 2004-09-30 | フォルシュングスインスティトゥート、ヒスチア、フェライン、フユール、クレプスフォルシュング | アサ抽出物から製造される医薬組成物 |
WO2006037981A1 (en) * | 2004-10-01 | 2006-04-13 | Gw Pharma Limited | Inhibition of tumour cell migration |
Non-Patent Citations (4)
Title |
---|
JPN6013038482; Medical Hypotheses Volume 66, Issue 2, 2006, Pages 234-246 * |
JPN6013038484; BRITISH JOURNAL OF PHARMACOLOGY 144, 2005, pp.1032-1036 * |
JPN6013038486; Mol. Neurobiol. 36, 2007, pp.60-67 * |
JPN6013038488; Journal of Pharmacology and Experimental Therapeutics 318(3), 2006, pp.1375-1387 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5611196B2 (ja) | カンナビノイドの組合せの抗腫瘍効果 | |
JP5674649B2 (ja) | 非カンナビノイド化学療法剤(例えばserm又はアルキル化剤)と組合せたカンナビノイド | |
GB2478074A (en) | THC and CBD for use in the treatment of tumours | |
GB2478072A (en) | THC and CBD for use in the treatment of brain tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110203 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120530 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131106 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140805 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140902 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5611196 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |